FDA grants RPDD to ReviR’s RTX-117 for CMT
The designation covers CMT as a whole and is not restricted to specific subtypes. The RPDD programme seeks to promote the development of therapies for rare, serious or
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m.
The regimens include Ziihera combined with Tevimbra (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy for patients with HER2+ immunohistochemistry (IHC) 3+ or IHC 2+/in situ hybridisation (ISH)+. The other
This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases. Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances